POTENT CONTRACTILE ACTIONS OF PROSTANOID EP(3)-RECEPTOR AGONISTS ON HUMAN ISOLATED PULMONARY-ARTERY

被引:80
|
作者
QIAN, YM
JONES, RL
CHAN, KM
STOCK, AI
HO, JKS
机构
[1] CHINESE UNIV HONG KONG,FAC MED,DEPT OBSTET & GYNAECOL,SHA TIN,HONG KONG
[2] CHINESE UNIV HONG KONG,FAC MED,DEPT SURG,SHA TIN,HONG KONG
[3] CHINESE UNIV HONG KONG,FAC MED,DEPT PHARMACOL,SHA TIN,HONG KONG
关键词
PROSTANOID RECEPTORS; HUMAN PULMONARY ARTERY; PROSTAGLANDIN E(2); SULPROSTONE; MISOPROSTOL; GEMEPROST; CICAPROST; TP-RECEPTOR ANTAGONISTS; POSTPARTUM HEMORRHAGE; OBSTETRIC COMPLICATIONS;
D O I
10.1111/j.1476-5381.1994.tb16997.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 In 13 of 15 experiments, prostaglandin E(2) (PGE(2)) and sulprostone (a prostanoid EF(1)/EF(3)-receptor agonist) contracted isolated rings of human pulmonary artery at low concentrations (greater than or equal to 5 and greater than or equal to 0.5 nM respectively). Tissue was obtained from patients undergoing surgery mainly for carcinoma of the lung. Characterization of the receptors involved was complicated by loss of sensitivity to the contractile PGE action over the experimental period. In contrast, contractile responses to KCl, phenylephrine and the specific thromboxane (TP-) receptor agonist, U-46619, did not decrease with time. 2 The relative contractile potencies for seven PGE analogues, measured during the first few hours after setting up the preparations, were as follows: sulprostone > misoprostol = gemeprost greater than or equal to PGE(2) greater than or equal to GR 63799X > 17-phenyl-omega-trinor PGE(2) greater than or equal to 11-deoxy PGE(1). This ranking indicates that an EP(3)-receptor is involved. 3 The contractile action of sulprostone was not blocked by the TP-receptor antagonists, EP 169 and GR 32191, and the EP(1)-receptor antagonist, AH 6809. 4 In two experiments, PGE(2) (50 nM) reduced basal tone and sulprostone was a weak contractile agent. Phenylephrine-induced tone was also inhibited by PGE(2) (EC(50) = 5-20 nM), 11-deoxy PGE(1) and butaprost (a selective EP(2)-receptor agonist); the latter prostanoids were about 2 and 4 times less potent than PGE(2) respectively. Interactions with phenylephrine were different in experiments where PGE(2) alone was contractile: PGE(2) induced contraction superimposed on the phenylephrine response and 11-deoxy PGE(1) induced either further contraction or had no effect. Butaprost produced relaxation at high concentrations; this may not be an EP(2) action since preparations were highly sensitive to relaxant actions of prostacyclin (IP-) receptor agonists (cicaprost and TEI-9063). 5 The study has shown that in the majority of experiments on the human isolated pulmonary artery, the contractile EF(3) system outweighed the relaxant EP(2) system. However, in two experiments the reverse was true. It is not clear to what extent these differences are due to disease processes affecting the tissues. The findings are discussed in relation to the adverse cardiovascular responses occasionally encountered during treatment of postpartum haemorrhage with sulprostone, and more generally to the clinical use of EP-receptor agonists in man.
引用
收藏
页码:369 / 374
页数:6
相关论文
共 50 条
  • [41] Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists
    Sharif, Najam A.
    Millar, J. Cameron
    Zode, Gulab
    Ota, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [42] Potent, selective agonists of the human β3-adrenergic receptor.
    Solvibile, WR
    Ashwell, MA
    Molinari, AJ
    Han, S
    Largis, E
    Mulvey, R
    Tillet, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U645 - U645
  • [43] Potent benzimidazolone based human β3-adrenergic receptor agonists
    Finley, Don R.
    Bell, Michael G.
    Borel, Anthony G.
    Bloomquist, William E.
    Cohen, Marlene L.
    Heiman, Mark. L.
    Kriauciunas, Aidas
    Matthews, Donald P.
    Miles, Tania
    Neel, David A.
    Rito, Christopher J.
    Sall, Daniel J.
    Shuker, Anthony J.
    Stephens, Thomas W.
    Tinsley, Frank C.
    Winter, Mark A.
    Jesudason, Cynthia D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (21) : 5691 - 5694
  • [44] Differential peristaltic motor effects of prostanoid (DP, EP, IP, TP) and leukotriene receptor agonists in the guinea-pig isolated small intestine
    Shahbazian, A
    Heinemann, A
    Peskar, BA
    Holzer, P
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (07) : 1047 - 1054
  • [45] Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonists
    Shum, WWC
    Le, GY
    Jones, RL
    Gurney, AM
    Sasaki, Y
    BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (08) : 1449 - 1461
  • [46] CONTRACTILE ACTIONS OF THROMBIN RECEPTOR-DERIVED PEPTIDES IN HUMAN UMBILICAL AND PLACENTAL ARTERY - EVIDENCE FOR RECEPTOR SUBTYPES
    TAYUYBOCO, J
    POON, MC
    HOLLENBERG, MD
    CLINICAL RESEARCH, 1994, 42 (02): : A334 - A334
  • [47] Human EP3I prostanoid receptor induces VEGF and VEGF receptor-1 mRNA expression
    Fujino, Hiromichi
    Taniguchi, Tomoko
    Israel, Davelene D.
    Regan, John W.
    Murayama, Toshihiko
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 289P - 289P
  • [48] Human EP3I prostanoid receptor induces VEGF and VEGF receptor-1 mRNA expression
    Taniguchi, Tomoko
    Fujino, Hiromichi
    Israel, Davelene D.
    Regan, John W.
    Murayama, Toshihiko
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 377 (04) : 1173 - 1178
  • [49] Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor
    Juteau, HN
    Gareau, Y
    Labelle, M
    Sturino, CF
    Sawyer, N
    Tremblay, N
    Lamontagne, S
    Carrière, MC
    Denis, D
    Metters, KM
    BIOORGANIC & MEDICINAL CHEMISTRY, 2001, 9 (08) : 1977 - 1984
  • [50] APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery
    Shen, L.
    Patel, J.
    Norel, X.
    Behan, D.
    Adams, J.
    Clapp, L. H.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1052 - 1052